Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Achieving target doses of angiotensin receptor-neprilysin inhibitor (ARNI) in heart failure with reduced ejection fraction (HFrEF) is often challenging due to concerns related to hypotension. This study evaluated dose-dependent effects of ARNI considering on-treatment blood pressure (BP).
Methods: From a multicenter HF registry, 1,097 HFrEF patients receiving ARNI for ≥6 months were stratified into low-dose (<100 mg/day, n = 249) and intermediate-to-high-dose (≥100 mg/day, n = 848) groups. Echocardiographic changes and clinical outcomes were compared across groups, considering on-treatment BP profiles (high-BP ≥ 110 mmHg vs. low-BP < 110 mmHg).
Results: Low on-treatment BP was independently associated with low-dose ARNI use. Both dose groups showed echocardiographic improvement, but the intermediate-to-high-dose group had more pronounced changes. Over 3.1 years (median follow-up), low-dose ARNI use was associated with a higher risk of mortality compared to intermediate-to-high-dose. These trends were consistently observed in both high-BP and low-BP profiles.
Conclusions: Low-dose ARNI use was associated with less improvement in myocardial function and worse clinical outcomes, even in patients with low-BP profiles. This highlights the importance of optimal ARNI dose titration despite low BP concerns.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12303280 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0328971 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Real-World Comparison of Treatment Outcomes for Multiple Myeloma in Elderly Transplant Ineligible Patients Receiving First-Line VRd, Rd and VCd: Results From the Australian and New Zealand Myeloma and Related Diseases Registry.
Clin Lymphoma Myeloma Leuk
August 2025
Middlemore Hospital, Auckland, New Zealand.
Background: Real-world data on treatment outcomes for elderly transplant-ineligible patients with newly diagnosed multiple myeloma are limited. The difference in treatment subsidization in Australia compared with New Zealand enables comparison of bortezomib-cyclophosphamide-dexamethasone (VCd), lenalidomide-bortezomib-dexamethasone (VRd) with Rd maintenance, and continuous Rd.
Methods: Using data from the ANZ Myeloma and Related Diseases Registry, we evaluated 1092 patients over 70 years of age between February 2013 and February 2024.
Prognostic Effects of Platelet Reactivity in Patients with Carotid Artery Stenting or Carotid Artery Endarterectomy: A Systematic Review and Meta-Analysis.
Curr Neurovasc Res
August 2025
Clinical Medical College of Chengdu Medical College, Chengdu, Sichuan, China.
Introduction: High On-Treatment Platelet Reactivity (HTPR) is frequently observed after carotid endarterectomy (CEA) or stenting (CAS), but its association with adverse events remains uncertain. This systematic review and meta-analysis evaluate the association between HTPR and recurrent vascular events in these patients.
Methods: EMBASE, PubMed, and Cochrane Library were searched for eligible studies from inception to July 1, 2024.
Synchronous Primary Early-Stage Non-Small Cell Lung Cancer: Trends in Management and Factors Associated with Improved Survival.
Ann Thorac Surg
September 2025
Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, Saint Louis, MO.
Background: Outcomes after multi-modality curative-intent treatment for patients with synchronous primary early-stage-I non-small cell lung cancer (SPELC) are inadequately understood.
Methods: We performed a retrospective study using the Veterans Health Administration database of patients diagnosed with two stage I SPELC who received treatment with either stereotactic body radiotherapy (SBRT) and/or surgery from 2006-2024. We evaluated utilization of SBRT and surgery as well factors associated with overall survival (OS) and disease-free survival (DFS) via Cox proportional hazard models.
Evaluation of Neutrophil to Lymphocyte Ratio in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With a Combination of Cetuximab and Nivolumab in a Phase II Clinical Trial.
Am J Clin Oncol
September 2025
Department of Head and Neck-Endocrine Oncology.
Objectives: We report on the biomarker analyses focusing on neutrophil-to-lymphocyte ratios (NLR) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with combined cetuximab and nivolumab.
Methods: Data were obtained from a phase II trial (NCT03370276). Peripheral blood NLR was obtained at baseline (B-NLR) and on-treatment (OT-NLR; 1 mo from treatment initiation).
A scoping review of clinical management guidelines in inborn errors of immunity.
J Allergy Clin Immunol
September 2025
University College London, Institute of Immunity and Transplantation, London, UK; Department of Immunology, Royal Free London NHS Foundation Trust, London, UK.
Background: A scoping review was conducted for the European Society for Immunodeficiencies (ESID) Clinical Working Party (CWP) to evaluate clinical management guidelines for Inborn Errors of Immunity (IEIs). The goal was to identify gaps to inform future guideline development, thereby supporting improved clinical practice and patient outcomes.
Methods: A search strategy was developed in collaboration with the ESID CWP and an information specialist.